Key result
DOACs show noninferiority to LMWH for recurrent events and major bleeding in cancer-associated VTE.
Why the study?
Anticoagulation for cancer-associated VTE is challenging with VKAs and LMWH, and until recently there were no large clinical trials assessing DOAC efficacy and safety in cancer patients.
Do direct oral anticoagulants (DOACs) reduce recurrent VTE and major bleeding compared to low-molecular-weight heparin (LMWH) in patients with cancer-associated venous thromboembolism?
Do direct oral anticoagulants (DOACs) reduce recurrent VTE and major bleeding compared to low-molecular-weight heparin (LMWH) in patients with cancer-associated venous thromboembolism?
Answers are grounded in this paper and cite their sources.
DOACs are a reasonable alternative to LMWH for treating cancer-associated VTE, though they should be used with caution in patients with gastrointestinal cancers due to an increased risk of bleeding.
Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications-including bleeding and potential drug-drug interactions with chemotherapy-associated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagulants (DOACs) could partially overcome these issues, but until recently there were no large clinical trials assessing their efficacy and safety in cancer patients. This review summarizes clinical treatment guidelines, prior clinical and real-world evidence for anticoagulant choice, recent clinical trials assessing DOACs for cancer-associated VTE (i.e. Hokusai-VTE Cancer, SELECT-D, CARAVAGGIO, and ADAM VTE), and special considerations for DOAC use. Based on established data, clinical guidelines recommend patients with cancer-associated VTE receive LMWH treatment of at least 3-6 months. Nevertheless, LMWH is underused and associated with poor compliance and persistence in these patients relative to oral anticoagulants. Clinical data supporting DOAC use in cancer patients are becoming available. In Hokusai-VTE Cancer, edoxaban was noninferior to dalteparin for the composite of recurrent VTE and major bleeding (12.8% versus 13.5%), with numerically lower recurrent VTE (7.9% versus 11.3%) and significantly higher major bleeding (6.9% versus 4.0%); only patients with gastrointestinal cancer had significantly higher risk of bleeding with edoxaban. In SELECT-D, rivaroxaban had numerically lower VTE recurrence (4% versus 11%), comparable major bleeding (6% versus 4%), and numerically higher clinically relevant nonmajor bleeding (13% versus 4%) versus dalteparin. Most bleeding events were gastrointestinal or urologic; patients with esophageal/gastroesophageal cancer had higher rates of major bleeding with rivaroxaban (36% versus 11%). For comparison of apixaban versus dalteparin, CARAVAGGIO is ongoing, and preliminary results from ADAM VTE are favorable. This review concludes that DOACs appear to be reasonable alternatives to LMWH for treatment of cancer-associated VTE. In patients with gastrointestinal cancer, DOAC use should be considered on a case-by-case basis with consideration of the relative risks and benefits.
No takes yet. Share an insight, caveat, or question.
Ay et al. (2019) conducted a review in cancer-associated venous thromboembolism. Direct oral anticoagulants (DOACs) vs. low-molecular-weight heparin (LMWH) was evaluated on composite of recurrent VTE and major bleeding. Direct oral anticoagulants appear to be reasonable alternatives to LMWH for cancer-associated VTE, with edoxaban showing noninferiority to dalteparin for recurrent VTE and major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: